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Abstract 
Ischemia reperfusion injury (IRI) is a common occurrence following myocardial infarction, transplantation, 
stroke and trauma that can lead to multiple organ failure, which remains the foremost cause of death in 
critically ill patients. Current therapeutic strategies for IRI are mainly palliative, and there is an urgent 
requirement for a therapeutic that could prevent or reverse tissue damage caused by IRI. Neutrophils are 
the primary responders following ischemia and reperfusion and represent important components in the 
protracted inflammatory response and severity associated with IRI. Experimental studies demonstrate 




neutrophil infiltration at the site of ischemia and show that inducing neutropenia can protect organs from 
ischemia reperfusion injury.  In this review, we highlight the mechanisms involved in neutrophil 
recruitment, activation and adherence and how this contributes to disease severity in IRI. Inhibiting 
neutrophil mobilization, tissue recruitment, and ultimately neutrophil-associated activation of local and 
systemic inflammatory responses may have therapeutic potential in the amelioration of local and remote 
tissue damage following IRI. 
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Clinical Setting of Ischemia Reperfusion  
Ischemia reperfusion (IR) has been recognised as a cause of clinical sequelae for over half a century 
(1) and remains a comon occurrence in coronary bypass surgery, organ transplantation, gut hypo-
perfusion and stroke (2,3).  IR is recognised as a complex cascade of events including interactions 
between vascular endothelium, interstitial compartments, circulating cells and numerous 
biochemical entities that follow ischemia. Inflammation is a key mediator of IR and aspects of the 
involvement of the innate immune system has been reviewed by others (3–5). Despite our 
knowledge of the pathophysiology of IR, injury caused by IR precedes clinical observation, and once 
apparent, it is often too late for intervention. Therefore, there is still a need for a therapeutic that 
could prevent or reverse the effects of the injuries caused by IR (2). A number of failed clinical trials 
demonstrated that intervention during the first seconds of reperfusion is imperative, and thus the 
window of opportunity during reperfusion is limited. Therefore therapeutic options need to be fast 
acting, readily available by clinicians and not adversely damaging in their own right.  
Causes and Effects of Ischemia Reperfusion Injury 
IR is initiated by an ischemic episode, where blood supply is restricted to a portion of an organ or 
the whole organ, initiating cell death which is further exacerbated when blood flow is returned. 
Ischemia results in tissue hypoxia that causes a build-up of metabolic intermediates and reactive 
oxygen species (ROS) namely, superoxide, hydrogen peroxide, and hydroxyl radicals. ROS species 
increase intracellular calcium, cause pH changes, and concomitantly deplete ATP, resulting in 
damage to cell organelles and leading to necrotic cell death (2,6). ROS production during short 
bouts of ischemia can be resolved by free radicals and antioxidants such as nitric oxide (NO). 




However, excessive periods of ischemia, ranging from a few minutes to half an hour or more (7–9), 
depending on the organ, cause irreversible effects which are amplified upon reperfusion.  
Reperfusion floods the ischemic tissue with oxygen. This activates metabolic intermediates and ROS 
resulting in  an overwhelming inflammatory response causing ischemia reperfusion injury (IRI). 
Increased ROS quenches the production of NO, damages endothelial cells resulting in loss of barrier 
integrity and release of ROS into the extracellular matrix (9,10). This increases expression of 
adhesion molecules (3); acts as a chemoattractant for neutrophils, initiating their recruitment (10); 
activates the complement cascade (11,12) and promotes apoptotic cell death (13,14). Resident 
macrophages and damaged endothelial cells release pro-inflammatroy cytokines further recruiting, 
activating and aiding in migration of neutrophils. This results in an overwhelming inflammatory 
response that if the body fails to regulate, can lead to acute respiratory distress syndrome (ARDS) 
and, or systemic inflammatory response syndrome (SIRS) which are central to the pathogenesis of 
multiple organ failure (MOF) (6,15–17), which has a 70% mortality rate (18). IRI physiology is 
complex, but indisputably the primary response cells to IRI are neutrophils, which can infiltrate the 
damaged tissue within minutes of activation. Several studies in the 1980’s and 1990’s investigated 
the role of neutrophils in IRI (19) but in the past two decades more emphasis has been given to 
molecular, rather than cellular, targets such as complement receptors (20), toll like receptors (21), 
reactive oxygen species (ROS) [20] and the pro inflammatory cytokines such as tumour necrosis 
factor-alpha TNF-α, which has subsequently been shown to not be involved in IRI (22). The role of 
cytokines, ROS, complement and toll like receptors cannot be ignored in IRI as they have a major 
role in the pathogenesis of IRI as they support, activate, recruit and amplify the destructive function 
of neutrophils. However, recent studies have returned focus to the role of neutrophils as a key 
player in the pathophysiology of IRI (12,23–25). Therefore we will highlight the interactions these 




have with neutrophils and how this creates a feedback loop of neutrophil recruitment and 
excessive damage at the site of IR and how this can result in MOF.    
Neutrophils in Ischemia Reperfusion Injury 
At the site of IR activated neutrophils further exacerbate host tissue damage through release of 
ROS, proteinases and cationic peptides (26). Neutrophils produce a large quantity of ROS when 
nicotinamide adenine dinucleotide phosphate (NADPH)-oxidase is activated upon adhesion or by 
pro-inflammatory cytokines (41).  Neutrophils block capillaries preventing reperfusion of the tissue, 
which leads to tissue necrosis and an exacerbated immune response. Neutrophils secrete pro-
inflammatory cytokines and chemokines to create a positive feedback loop of neutrophil 
recruitment and activation (12,28), as illustrated in Figure 1. Furthermore, neutrophil migration 
causes loss of epithelial barrier integrity and down regulation of junctional adhesion molecule 
(JAMC). JAMC prevents reverse migration of neutrophils (29), which is associated with ARDS, SIRS 
and MOF (15,22,26). Ischemia reperfusion can affect every part of the body and is initiated by 
various mechanisms depending on the organ or area involved. Therefore the overactive state of 
neutrophils in response to excessive ROS, which is also present in normal tissues at lower levels, 
rather than activation induced via cytokine signalling , could be one reason why a therapeutic to 
treat or prevent IRI remains elusive. 
We will therefore explore the role of neutrophils in specific organs, the mechanisms involved in IRI 
in that organ and how neutrophils contribute to disease severity regardless of the mechanisms 
involved in recruiting and activating them.  
 





Figure 1: Positive feedback loop of cytokine release and neutrophil recruitment. Ischemic tissue and resident 
macrophages at the site of ischemia release reactive oxygen species (ROS) and cytokines. ROS activates complement 
and drives chemotaxis of neutrophils into the ischemic tissue, along with IL-1 and C5a which initiate rapid 
neutrophilia. Complement proteins and cytokines bind to activated neutrophils at the site of ischemia. This promotes 
production of further pro-inflammatory cytokines and up-regulates expression of adhesion molecules. C5a binds to 
the C5a receptor (C5aR) on neutrophils and stimulates NFκB which initiates transcription of TNF-α, IL-8 and IL-6. TNF-
α promotes production of IL-1 and up-regulates expression of CD11/CD18 integrins, which are required for firm 
adhesion to the epithelial/endothelial cell, enabling migration across the endothelial/epithelial barrier. IL-8 
promotes neutrophilia and IL-6 stimulates granulopoiesis in the bone marrow. This overwhelming response of 
neutrophil infiltration and cytokine production overrides protective mechanisms leading to a positive feedback loop 
of neutrophil mobilization, production, recruitment, migration and subsequently excessive damage beyond that of 
the initial insult. 
Neutrophils in organ specific IR injuries 
Heart 
Cardiac IR is common after coronary bypass surgery with myocardial infarction being the leading 
cause of mortality and morbidity in adults in developed and developing nations (30). After 




prolonged ischemia restoration of blood flow induces ROS and production of TNF-α, IL-1, IL-6, IL-8, 
peptide activating factor (PAF) and macrophage inflammatory factor 2 (MIP-2) by endothelial cells, 
mast cells and myocytes (31). It also activates complement initiating production of C5a (20). These 
events significantly increase neutrophil infiltration at the site of IRI which directly correlates to 
infarct size (31). Adhesion molecules, such as CD11, CD18, P-selectin and ICAM-1 on the 
endothelium are also upregulated which activate neutrophils and enable migration through the 
endothelium. Neutrophils have deleterious effects in three ways. Firstly they release a large 
amount of ROS which exacerbates tissue damage (10). This was verified in a dog model, by electron 
paramagnetic resonance spectroscopy which showed neutrophils as the major source of ROS during 
reperfusion (32). Secondly, they contribute to the no-reflow phenomenon. This can expand the 
ischemic insult to over 50% of the capillaries exacerbating tissue damage and necrosis and thus 
upregulating  pro-inflammatory signals, adhesion molecules and neutrophil infiltration (31,33), 
through the neutrophil feedback loop (Figure 1). Finally, enthusiastic migration of neutrophils 
across the endothelial barrier leads to tight junction loss (31,34) and potentially MOF.    
Various animal models inducing neutropenia in feline, canine, bovine and rodents have exhibited 
reduced tissue necrosis and myocardial injury (35,36), as well as demonstrating preservation of 
endothelial function (37). Chandrasekhar and colleagues investigated the role of the pro-
inflammatory cytokines IL-6, IL-1β and TNF-α demonstrating that neutrophil depletion in rats 
significantly inhibited expression of these cytokines independently of NF-κβ (38). Knockout models 
of P-selectin (39,40) and ICAM-1 (40,41) further corroborate the damaging role of neutrophils in IRI 
as myocardial necrosis in mice was attenuated in relation with reduced neutrophil infiltration. 





IRI is a major cause of acute kidney injury (AKI) which has a mortality rate in critically ill patients 
around 50% and causes significant comorbidity (3,42,43). Neutrophil infiltration in kidney IRI is seen 
as early as thirty minutes after reperfusion and is evident in both animal models and patient 
biopsies (25). Awad and colleagues recently carried out an extensive study on the role of 
neutrophils in kidney IRI in a murine model that clamps the renal pedicles to induce IRI (43). They 
showed that neutrophil transmigration into the interstitial compartment is responsible for vascular 
permeability and damage in the kidney. 
IRI causes injury to tubular epithelial cells, endothelial cells and resident dendritic cells (DC). 
Resident DC’s  produce TNF-α, IL-6, MCP-1, RANTES (44), MIP-2 and keratinocytes-derived 
chemokine (the mouse analogue of human IL-8)(42), initiating a potent chemotactic gradient for 
neutrophil recruitment. Interestingly in the kidney IL-8 plays a crucial role in neutrophil recruitment 
and mediates tissue injury via cytokines, free radical intermediates and proteases (42,44). Increased 
expression of ICAM-1, P-selectin and IL-8 (45), enables increased adhesion which has been 
attributed to nephron destruction (46). Upon degranulation neutrophils release proteases, 
myeloperoxidase (MPO), cytokines and generation of ROS in the outer medulla (42) broadening 
tissue damage throughout the kidney. Furthermore neutrophils in conjunction with platelets and 
red blood cells cause blockage to the capillary resulting in the no-reflow phenomenon (25) which 
amplifies the inflammatory response and thus neutrophil infiltration. Activation of the complement 
system, specifically C3, C5a and membrane attack complex (MAC; C5b-9) are also seen in kidney IRI 
(42,47). MAC deposition stimulates TNF-α  and IL-6 and down regulates Crry, a complement 
inhibitor on the tubular epithelium (42).  





Lung IRI can be initiated by several conditions including lung transplantation, cardiopulmonary 
disease, trauma, resuscitation, atherosclerosis and pulmonary embolism and remains a significant 
cause of morbidity and mortality (48). Lung IRI can also be initiated from ischemic insult in other 
organs such as the intestine. Lung injury after intestinal IR is characterised by increased 
microvascular permeability, alveolar capillary endothelial cell injury, reduced lung tissue ATP levels 
and neutrophil infiltration (49). 
Production of ROS is immediately induced upon reperfusion, primarily from alveolar macrophages 
and endothelial cells. NFκB, NADPH-oxidase, iNOS and the pro-inflammatory cytokines IL-8, IL-12, 
IL-18, TNF-α and PAF are activated. These amplify the expression of ICAM-1, CD18 and P-selectin on 
the endothelial side of the lung (48). These events begin to impair lung function and recruit 
neutrophils, which generate additional ROS, IL-8, PAF, TNF-α and MPO. Neutrophils are particularly 
damaging during this phase as they increase lung permeability and facilitate tissue damage (50). 
Neutropenia induced in a rat model provides protection from tissue damage corroborating that 
neutrophils are key in the severity of tissue damage (51). Although IL-8 correlates directly to 
mortality rate after lung transplantation (48) it predominantly induces chemotaxis in neutrophils 
(52); indicating that higher mortality rates are most likely due to the damage caused by infiltrating 
neutrophils rather than IL-8 itself.  
Liver 
The role of neutrophils in liver IR was well defined by Jaeschke and colleague in the early 90’s and 
showed that neutrophils exacerbate liver damage (53). More recently reviews by Ramaiah and 
Jaeschke 2007 (24) and Kubes and Mehal 2012 (54), provide compelling evidence for the role of 
neutrophils in liver IR. MIP-2 and keratinocyte chemoattractant are the main chemoattractants in 




the liver along with TNF-α , IL-1β and IL-8 promoting neutrophil accumulation and expression of the 
CD11/CD18 integrin (24). In the liver neutrophils adhere within sinusoids independently of selectins 
eliminating the requirement of rolling (54). However, activation and accumulation of neutrophils in 
the sinusoids do not cause tissue damage to the epithelium, as it does in other organs. Only after 
migrating across the endothelium and in close proximity to the hepatocytes can neutrophils cause 
damage by oxidative stress, triggered through interaction with CD11/CD18 integrins, NADPH 
oxidase and MPO (24,55). Transendothelial neutrophil migration therefore is an important step in 
liver IR which is controlled by expression of CD11/CD18 and the subsequent binding to ICAM-1 
(56,57). This was further corroborated by Jasechke and colleagues in 2012(55), when they identified 
the role of complement in directly priming neutrophils for ROS formation and activation of CD11b 
expression. They also showed that complement promotes Kupffer cell induced oxidant stress and 
injury which indirectly enhances neutrophil responses (55). The role of neutrophils in liver IR is 
further supported through the protective effects seen in animal models of neutropenia (58,59). 
Although neutropenia is protective, inducing neutropenia in clinical patients would severely 
immunocompromise them making them susceptible to many pathogenic diseases. This is why we 
need to focus on modulating neutrophil behaviour rather than preventing it completely. 
Gut 
Intestinal ischemia reperfusion has a relatively small incidence rate with only 30,000 cases reported 
per annum in the USA and has therefore not been given as much attention as other organs. 
However, intestinal IR is often a secondary event to most critical conditions (60), with severe 
secondary events being associated with atherosclerosis, obesity, diabetes (12,61) and α-adrenergic 
agents or digitalics (16).  




Recent evidence reveals neutrophils are a key player in the pathophysiology of intestinal IRI 
(12,23,62), and our histological staining of mouse ileum illustrates neutrophil infiltration and villi 
destruction (Figure 2). Importantly, neutrophil depletion has shown to protect the intestine from 
late stage mucosal damage and afford protection to remote organs (63–66).   
 
Figure 2: Mouse epithelium showing neutrophil infiltration. Intestinal ischemia reperfusion (IR) increases granulocytic 
neutrophil infiltration in the intestine, accompanied with destruction of villi (loss of epithelial integrity). Representative 
sections of ileum from (A) Sham-operated wild-type mice (WT – SHAM) mice and (B) Intestinal IR wild-type mice (WT - 
IR) showing infiltrating neutrophils (stained red/pink) in the villi of small intestine as indicated by arrows. Granulocytic 
neutrophils were identified by staining specific leukocyte esterase present predominantly in granulocytic neutrophils. 
WT-IR mice were subjected to IR surgery in which the superior mesenteric artery was ligated for 30 min and released 
(reperfused) for 150 min. WT-SHAM mice underwent the same surgery procedures without the artery being ligated. 
Tissues were collected, PFA fixed and post-processed for the esterase stain (Unpublished data 2013).  
 
The initial insult, as is characteristic with IR in all organs, is from ROS.  ROS themselves are key 
mediators in intestinal IRI; they are a primary source of damage initially compromising the integrity 
of the endothelial barrier (7,9,67); promote activation of complement; attract neutrophils and 
enhance expression of cell adhesion markers increasing extravascular migration to the sites of 
inflammation resulting in vascular injury (12,28,68).  
Complement is activated independently through ROS and neutrophil activation and leads to the 
production of C5a and IL-1β, potent chemoattractants for neutrophils. C5a further stimulates NFκB 
upregulating transcription of pro-inflammatory cytokines recruiting more neutrophils (7,69). C5aR 




knockout models show reduced intestinal mucosal damage, decreased neutrophil infiltration, 
attenuate neutrophil apoptosis and prevent cytokine release into the plasma (70). TLR2 and TLR4 
contribute to the initiation of an inflammatory response (4) as they signal macrophages, monocytes 
and dendritic cells to further recruit neutrophils through production of cytokines. TNF-α up-
regulates expression of CD11/CD18 which forms firm adhesion with ICAM-1 and P-selectin (71,72). 
In intestinal IRI IL-8, which is secreted from the basolateral surface of the intestinal epithelium, is 
important for initialising neutrophil migration across the epithelium (73) and neutrophil 
degranulation (74). Blocking IL-8 in a transgenic mouse model has shown to mitigate intestinal IRI 
[83]. Platelet levels are increased in parallel to leukocytes in intestinal IRI and bind to neutrophils 
increasing their adhesive capabilities to the endothelium independently of IL-8. Production of  ROS 
and PAF (76) amplifies neutrophil numbers, pro-inflammatory cytokines and ROS which, fuel tissue 
damage  increase vascular permeability (12).  
We recently showed that neutrophil mobilization from bone-marrow, or peripheral pools, following 
ischemia, plays a key role in inducing intestinal IR injury (23). Importantly, intestinal complement 
activation was observed after IR, and corresponds with increased circulating neutrophils. Blocking 
the major complement activation fragment receptor C3aR worsened injury, by increasing the 
number of mobilized neutrophils in both the circulation and intestine. This intestinal neutrophil 
infiltration could in turn be blocked by inhibiting the C5a receptor (C5aR), thereby ameliorating 
intestinal IR pathology. This recent study highlights the importance of the neutrophil and its entry 
into the blood and subsequently the intestine, in the establishment of intestinal IR injury.  
Neutrophils and Multiple Organ Failure (MOF) 
IRI in any organ can result in SIRS, ARDS and MOF. In intensive care units 50% of deaths are 
attributed to MOF (77) and ARDS is fatal in over 40% of patients (26). Neutrophil migration in IRI is 




an important part of excessive damage in all organs as highlighted in previous sections and reverse 
migration has been related to systemic inflammation after remote IR events. Woodfin and 
colleagues demonstrated this event in a mouse model that initiates IRI in the cremaster muscle or 
lower limb. Using 3D and 4D imaging technology they observed down regulation of JAMC, which 
usually prevents reverse migration, and transendothelial neutrophil migration (78) which has been 
depicted in Figure 3. Neutrophils that undergo reverse migration exhibit enhanced ROS generation 
and more resistance to apoptosis contributing to systemic inflammation and secondary organ 
damage (78). Further support for the role of these neutrophils in MOF is a clinical trial analysing the 
role of neutrophils in the circulatory and lymphatic system of mesenteric IRI. Disruption of the tight 
junctions increased vascular permeability. This enabled neutrophils and enteric bacteria to 
translocate into the circulatory and lymphatic system, Neutrophils now primed for enhanced ROS 
production damage in remote organs, which is highly attributed to ARDS and MOF (15). These 
findings further substantiate the need for a therapeutic that can reduce the excessive inflammatory 
response caused by IRI and show how critical neutrophils are in IRI. 
 
Figure 3: Neutrophil migration is initiated by various chemotactic agents produced at the site of IR. Neutrophils produce ROS and 
inadvertently destroy local endothelial or epithelial cells that were unaffected by the initial IR insult. Neutrophils become more 
resilient to apotosis and gain enhanced ROS production. JAMC is disrupted by neutrophil proteases and cell disruption enabling 
neutrophils to migrate out of the tissue, essentially reverse migration. It can now migrate to other organs and destroy tissues 
through ROS production leading to ARDS, SIRS or MOF. 




Neutrophil targeting therapeutics to treat IRI 
To date most therapeutics have targeted cytokines, complement, free radicals, platelet aggregating 
factor and adhesion molecules in an attempt to resolve the adverse effects of IRI. So far, such 
agents have been relatively ineffective clinically (7,60,69). Current therapeutic options for IR are 
merely palliative, offering some relief to the patients discomfort, but failing to improve the 
underlying condition (79). 
One trialled treatment for IRI has been to increase the levels of NO prior to surgery, as many animal 
studies supplemented with antioxidants demonstrated reduced IRI. During an ischemic state, 
production of NO is shut down. Upon reperfusion, the ischemic tissue is overloaded with 
superoxides that quench any remaining NO and produce highly toxic peroxynitrite. Production of 
superoxides in IRI eventually lead to inactivation of NO altogether (12). Unfortunately, increasing 
levels of NO in tissue prior to ischemia exacerbated IRI (2). Alternate antioxidant treatments such as 
Allopurinol, Superoxide dismutase (SOD), iron chelators, N-acetyl cysteine, ethanol, Captopril and 
Verapamil have also failed to provide conclusive evidence for clinical end point success in animal 
and clinical trials (80,81). Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a potent free radical 
scavenger, improved survival and renal function in rats subjected to renal IRI (82) and has had 
success in a clinical pilot study of acute myocardial infarction (83). Recently, stobadine, a novel 
synthetic pyridoindole antioxidant, which diminishes lipid peroxidation and protein impairment by 
free radical scavenging and anti-oxidant activity, has been shown to provide significant protection 
from IRI in rat kidneys (44). Based on evidence showing Hydrogen Sulphide (H2S) as a modulator of 
inflammatory events through interaction with leukocytes (84), Sivarajah and colleagues 
investigated its role in myocardial IR. They demonstrated that H2S decreases myocardiocyte 
apoptosis and ICAM-1 expression and neutrophil infiltration (13). 




Initial success has been established in pre-clinical models of IRI for a handful of therapeutics that 
target neutrophils. A monoclonal antibody targeted against the CD11/CD18 integrin showed 
promising results in animal models (85–87), but clinical trials failed to show a significant reduction 
in infarct size (88,89). G protein-coupled receptors (GPCR’s) have been very successful for a range 
of disorders and, account for almost a third of all prescription drugs in current use (90). Evidence to 
date indicates they may also be successful targets for IRI. G protein-coupled receptor 43 (GPR43), 
which is highly expressed on neutrophils (91), is a receptor for short chain fatty acids (SCFA’s). 
These have shown to reduce the degree of IRI in rat gut using a model of mesenteric ischemia 
reperfusion (92). Therefore modulation of neutrophils through GPR43 could be a possible future 
avenue to modulate neutrophil recruitment to organs following IRI. Another GPCR, adenosine 2A 
(A2A) receptor, also has protective effects. It reduced infarct size  in a pig model of myocardial IR 
(93) and, inhibited adhesion molecules on endothelial cells and reduced neutrophil numbers in a 
mouse model of kidney IR (94) 
Complement inhibition is another attractive target. Gut, liver, kidney, limb and brain models have 
revealed the role of complement as a key mediator of post ischemic damage (95,96). Further 
studies supplement these findings, showing that complement inhibitors such as recombinant sCR1 
do reduce IRI in various organs (6,72,97–100). However, complement inhibitors have the drawback 
that they have to block tissue injury whilst preserving its function to prevent infection and eliminate 
immune complexes; failure to do this leaves the patient severely immunocompromised and 
susceptible to infection (101). To date, eculizumab is the only clinically available therapeutic that 
specifically targets the complement system, and is approved for use in Paroxysmal nocturnal 
hemoglobinuria (PNH) and atypical haemolytic-uremic syndrome (aHUS) (102). It specifically targets 
C5, preventing its cleavage into C5a; a potent chemoattractant and C5b which forms MAC. C5a is an 




important chemoattractant for neutrophils and therefore blocking C5 could reduce neutrophil 
infiltration in IRI. Unfortunately pexelizumab, a close analogue to eculizumab that also inhibits 
cleavage of C5, failed to reduce infarct size in a human myocardial infarction trial (103). In animal 
models of IR complement depletion significantly reduced neutrophil numbers and decreases lung 
permeability (104). Hence there is a strong possibility that reduction of IRI when inhibiting 
complement is actually due to a reduction in neutrophil infiltration, inferring that a therapeutic 
intervention that targets neutrophils specifically could be the key to preventing IRI. In support of 
this hypothesis, we recently demonstrated that infusion of C3a agonist peptide to mice reduced 
neutrophil mobilization after intestinal IR, which resulted in reduced tissue neutrophil infiltration 
and ameliorated disease pathology (23). 
Future trends 
Many failures have been observed in an attempt to prevent and treat ischemia reperfusion injury 
(IRI). These failings could be due to a number of reasons, from a lack of understanding of the 
pathophysiology to insufficiency of the disease models. A main hurdle in drug development is the 
translation of the efficacy in animal models to humans. Clinical trials for therapeutics that target 
inflammatory responses have been particularly fruitless in the treatment of IRI, with promising in 
vivo data in animal models failing to relate clinically. The success of therapeutics could be restricted 
by the availability of models that can truly reflect in vivo biology, which has been highlighted 
recently in a number of reviews (105–107). Furthermore, current studies generally use or target 
only one component that impedes activation or migration of neutrophils. Targeting several key 
factors at the same time could provide better protection from IRI without compromising any one 
area of the immune system and thus resulting in better patient outcomes.  




In reality, the insult from ischemia reperfusion is multifactorial and a therapeutic that targets a 
single molecular aspect of pathology will most likely continue to be ineffective. As such, 
therapeutics should aim to target multiple pathways, or indeed whole cells such as the neutrophil, 
to maximise the impact of reducing the inflammatory response caused by IRI. Ischemia reperfusion 
can occur in just about every part of the body and has a plethora of aetiologies that are specific to 
the initial insult, area and organ in which it takes place. Regardless, it is apparent that all 
mechanisms lead to recruitment and activation of neutrophils, which have been shown to correlate 
with disease severity. Therefore the ultimate therapeutic or combination of therapeutics would 
ideally dampen the inflammatory signals that mobilize and recruit neutrophils or regulate 
neutrophils directly in order to prevent IR developing into IRI. 
Conclusion 
IRI is common during various traumatic and surgical events and responsible for ARDS and MOF, 
which causes death in over half of all patients affected. Various strategies have been employed to 
prevent the adverse effects of IR but the complex pathophysiology of IR continues to evade 
treatment. The inflammatory response is indubitably a key mediator of IRI. In addition, this review 
has emphasised the importance of neutrophils as a significant contributor to the progression of IRI. 
Neutrophils contribute to the severity of IRI by exacerbating ischemia through blockage of 
capillaries (no-reflow phenomenon); escalating the inflammatory response by releasing cytokines; 
damaging cells unaffected by ischemia through release of ROS and potentially most significantly, by 
disrupting the endothelial and epithelial barriers which leads to MOF. Therapeutics have targeted 
several pathways involved in the pathophysiology of IRI but so far have failed to provide an 
effective therapy to ameliorate outcomes. This review has highlighted the underlying and necessary 
role of neutrophils in IRI. Further understanding of the mechanisms involved in mobilization, 




transmigration and activation of neutrophils in IRI, could lead to a potential therapeutic target that 
can prevent the onset of IRI. 
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